SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers.
Sunesis Pharmaceuticals Inc, under license from Dainippon Sumitomo Pharma Co Ltd, is developing SNS-595, a naphthyridine cell cycle inhibitor and apoptosis stimulator, for the potential treatment of a variety of solid and hematological malignancies. Phase I clinical trials had been completed in several solid tumor types and phase II clinical trials had been completed in patients with small-cell lung cancer and NSCLC. A phase II clinical trial in patients with platinum-resistant ovarian cancer and phase I/II and phase II clinical trials in patients with acute leukemias were ongoing at the time of publication.
The University of New Mexico Cancer Center, 900 Camino de Salud, NE, Albuquerque, NM 87131, USA.
David A
DA
Mills
Houman M
HM
Fekrazad
Claire F
CF
Verschraegen
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D002453:Cell Cycle / Q000187:drug effects; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D000075202:Contraindications; D006801:Humans; D009287:Naphthyridines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*; D010330:Patents as Topic; D016032:Randomized Controlled Trials as Topic; D013329:Structure-Activity Relationship; D013844:Thiazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009287:Naphthyridines; D013844:Thiazoles; C485113:vosaroxin